Although the majority of EGFR-positive NSCLC patients harbor a single EGFR mutation, recent advances in next-generation sequencing (NGS) technologies have revealed that around 10% of patients harbor compound EGFR mutations, defined by the presence of double or multiple distinct EGFR genetic alterations at baseline [18–20]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.